Role of pharmacodynamics in designing dosage regimens for β-lactams

Connecticut Medicine

Volumn 67, Issue 5, 2003, Pages 265-268

  Kotapati, Srividya ^a   Kuti, Joseph L ^b   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG STABILITY; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; STEADY STATE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PENICILLANIC ACID; PIPERACILLIN; THIENAMYCINS;

EID: 0038780755     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Turnidge JD: The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22.
2. Nicolau DP, McNabb J, Lacy MK, et al: Continuous vs intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
3. McNabb J, Nightingale CH, Quintiliani R, et al: Cost-effectiveness of ceftazidime continuous infusion vs intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001; 21:549-55.
4. Richerson MA, Ambrose PG, Bui KQ, et al: Pharmacokinetic and pharmacoeconomic evaluation of piperacillin-tazobactam administered as either continuous or intermittent infusion with once daily gentamicin. IDCP 1999; 8:195-200.
5. Hitt CM, Patel KB, Nicolau DP, et al: Influence of piperacillintazobactam on pharmacokinetics of gentamicin given once daily. Am J Health-Syst Pharm 1997; 54:2704-8.
6. Burgess DS, Waldrep T: Pharmacokinetics anti pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing. Clin Ther 2002; 24:1090-104.
7. Jones RN, Croco MA, Kugler KC, et al: Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibiltiy patterns from the SENTRY antimicrobial surveillance program (United States and Canada. 1997). Diagn Microbiol Infect Dia 2000; 37: 115-25.
8. Kuti JL, Nightingale CH, Quintiliani R, et al: Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002; 44:51-7.
9. Grant EM, Kuti JL, Nicolau DP, et al: Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillintazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22:471-83.
10. Lomaestro BM, Rodvold KA, Danziger LH, et al: Pharmacodynamic evaluation of extending the infusion time of piperacillin, tazobactam doses using Monte Carlo analysis [abstract]. In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology. 2001:36.
11. Kim MK, Xuan D, Quintiliaui R, et al: Pharmacokinetic and pharmacodynamic profile of high dose extended interxal piperacillin-tazobactam. J Antimicrob Chemother 2001; 48: 259-67.
12. Paterson DL, Clarke L, Ndirangu MW, et al: Use of pharmacodynamic principles and stochastic modeling to choose an optional empiric cefepime dose for suspected Pseudomonas aeruginosa infections within a single institution [abstract]. In: Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 2002:9.
13. Burgess DS, Hastings RW, Hardin TC: Pharmacokmetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22:66-75.
14. NCCLS: Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. NCCLS. 940 West Valley Road, Suite 1400. Wayne, PA 19087-1898. USA. 2002.
15. Kuti JL, Maglio D, Nightingale CH, et al: Economic benefit of a meropenem dosing strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2002; 60:565-8.
16. Dandekar PK, Maglio D, Sutherland CA, et al: Pharmacokinetics of meropenem 0.5 g and 2 g every 8 hr administered as a 3 hr infusion [abstract]. In: Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology. 2002:18.
17. Kuti JL, Dandekar PK, Nightingale CH, et al: Pharmacodynamic comparison of prolonged and traditional infusions of meropenem in gram negative bacteria [abstract]. In: Programs and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology. 2002:8.